Beijing Tide Pharmaceutical Co., Ltd.

Yanping Zhao

Hongjun Wang

Liying Zhou

Yuanyuan Jiang

Yanan Liu

Jing Li

Gong Li

Kai Liu

Yeming Wang

Ning Shao

Fengping Xiao

Jianmei Pang

Huai Huang

Weiting Zhong

Fajie Li

Zhenguang Zou

Xuelian Liu

Jing Zhao

Yu Wang

Zewang Feng

Jie Meng

Xichao Chen

Shenzhen Fu

Yixin He

Nana Tian

Yun Wu

Weina Liu

Yong Xie

Xiaoqian Wang

Yanhao Zhang

Zhaolu Zhu

Di Lu

Huining Liang

Futian Fan

CheungLing Cheng

Xiang Li

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

The present invention falls within the field of biological medicine, and specifically relates to a method for preventing, alleviating and/or treating fatty liver disease and/or steatohepatitis. The method comprises administering, to an individual in need thereof, an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, an ester, a stereoisomer, a polymorph, a solvate, an N-oxide, an isotopically labeled compound, a metabolite or a prodrug thereof.

Method for treating fatty liver disease and/or steatohepatitis

The present invention relates to a salt of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-diamine and a solid form thereof, a method for preparing the solid form and a pharmaceutical composition comprising the solid form, as well as a use of the solid form for preventing or treating diseases modulated by P2X3 and/or P2X2/3 receptor antagonists.

Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof

Provided is an EGFR kinase inhibitor according to general formula (I) and a pharmaceutical composition containing the inhibitor. The invention can be used to treat diseases related to EGFR kinase, such as cancer. Also provided is a preparation and use of the above inhibitor.

Compound for inhibiting and inducing degradation of EGFR kinase

A Rho-associated protein kinase (ROCK) inhibitor represented by formula (I), a pharmaceutical composition comprising same, and a use thereof for preventing or treating ROCK-mediated diseases.

Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof

The present invention relates to a solid form of 5-((2-ethynyl-5-isopropylpyridin-4-yl)oxy)pyrimidine-2,4-diamine or a hydrate thereof, a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and a use of the solid form for the prevention or treatment of a disease modulated by P2X3 and/or P2X2/3 receptor antagonists.

Solid form of diaminopyrimidine compound or hydrate thereof, preparation method therefor, and application thereof

The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.

Receptor inhibitor, pharmaceutical composition comprising same, and use thereof

The present invention relates to the field of biomedicine, particularly to double-stranded RNA molecules targeting CKIP-1 and uses thereof, particularly to use of the double-stranded RNA molecules for the treatment of inflammatory diseases such as arthritis, particularly rheumatoid arthritis.

Double-stranded RNA molecule targeting CKIP-1 and use thereof

The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.

Pregabalin sustained release composition and method for preparing the same

P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.

Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof

The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof. 

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist. 

The present invention relates to a Rho-associated protein kinase inhibitor of formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and a use of the same in preventing or treating a disease mediated by Rho-associated protein kinase (ROCK). 

Growing community of inventors

Beijing, China

Yanping Zhao